Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi Pharmaceutical (KRX: 128940) to develop a combination therapy using MSD’s top-selling anti-PD-1 therapy Keytruda (pembrolizumab) and Hanmi’s bispecific antibody (BsAb) BH3120 for the treatment of progressive or metastatic solid tumors. The financial details of the agreement were not disclosed.
BH3120 is an innovative immuno-oncology therapy that targets both PD-L1 and 4-1BB, designed to stimulate potent anti-tumor responses while minimizing immune activation in healthy tissues. This approach aims to enhance the therapeutic index compared to other anti-4-1BB candidates. The bispecific antibody was developed using a proprietary platform by Hanmi and its Chinese subsidiary, Beijing Hanmi Pharmaceutical (BJHM).- Flcube.com
